Shopping Cart
Remove All
Your shopping cart is currently empty
Rimtuzalcap
🥰Excellent
Catalog No. T9522Cas No. 2167246-24-2
Alias CAD-1883
Rimtuzalcap (CAD-1883) (CAD-1883), a pioneering selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels), is employed in the study of movement disorders such as spinocerebellar ataxia (SCA) and essential tremor (ET).
Rimtuzalcap
🥰Excellent
Purity: 99.64%
Catalog No. T9522Alias CAD-1883Cas No. 2167246-24-2
Rimtuzalcap (CAD-1883) (CAD-1883), a pioneering selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels), is employed in the study of movement disorders such as spinocerebellar ataxia (SCA) and essential tremor (ET).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 5 mg | $71 | In Stock | In Stock | |
| 10 mg | $113 | In Stock | In Stock | |
| 25 mg | $227 | In Stock | In Stock | |
| 50 mg | $337 | In Stock | In Stock | |
| 100 mg | $476 | In Stock | In Stock | |
| 200 mg | $666 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.64%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | Rimtuzalcap (CAD-1883) (CAD-1883), a pioneering selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels), is employed in the study of movement disorders such as spinocerebellar ataxia (SCA) and essential tremor (ET). |
| In vitro | Rimtuzalcap (Compound 1), a small-molecule modulator of potassium ion channels, exhibits significant therapeutic promise for addressing a range of diseases. These diseases are marked either by the dysfunction of potassium ion channels or by other factors affecting these channels[1]. |
| In vivo | Rimtuzalcap (CAD-1883) effectively decreases Purkinje cell firing rate by about 40%, aligning with its expected therapeutic action of enhancing SK channel activity through positive allosteric modulation. When applied in sequence, either 1 or 3 µM of CAD-1883 can partially reverse the augmented coefficient of variation in interspike intervals noted in cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice[1]. |
| Synonyms | CAD-1883 |
| Molecular Weight | 378.42 |
| Formula | C18H24F2N6O |
| Cas No. | 2167246-24-2 |
| Smiles | Cc1ccn(n1)-c1nc(NC2CCC(F)(F)CC2)cc(n1)N1CCOCC1 |
| Relative Density. | 1.42 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (660.64 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (13.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Rimtuzalcap | purchase Rimtuzalcap | Rimtuzalcap cost | order Rimtuzalcap | Rimtuzalcap chemical structure | Rimtuzalcap in vivo | Rimtuzalcap in vitro | Rimtuzalcap formula | Rimtuzalcap molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.